trending Market Intelligence /marketintelligence/en/news-insights/trending/-j01Pz-EKEkK_0TB6jah4g2 content esgSubNav
In This List

AbCellera, Pfizer partner to conduct antibody research

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


AbCellera, Pfizer partner to conduct antibody research

AbCellera Biologics Inc. and Pfizer Inc. entered a collaboration agreement for the discovery of new therapeutic antibodies.

AbCellera will use its proprietary monoclonal antibody screening platform to find function-modulating antibodies against undisclosed membrane protein targets.

Under the terms of the agreement, AbCellera will receive an upfront payment and research support and will be eligible to receive up to about $90 million in contingent milestone payments, as well as tiered mid-to-low single digit royalty payments based on Pfizer's development and commercialization of antibodies that may be generated under the collaboration.

Further terms of the agreement are not disclosed.